© 2026 Nanjing Finechem Holdings Co., Ltd,
All Right Reserved
Diclofenac remains one of the core nonsteroidal anti-inflammatory drugs, indispensable from pain management in the United States and Canada to hospitals in Germany, India, Brazil, and South Korea. When talking about system suitability, the focus turns quickly to the quality and consistency of raw materials, regulatory pathways, and—most crucially—the cost structures which supply chains in China, the European Union, and the USA bring to the table. Years ago, manufacturers sourced active pharmaceutical ingredients from Europe or the United States, drained by high compliance costs, labor rates, and an endless maze of regulations. Now, China stands at the center of the global bulk-drug supply, not just for diclofenac but for a host of finished dosage forms and intermediates sold across Japan, the UK, France, Italy, Saudi Arabia, Australia, Spain, Indonesia, and Mexico. Think of the people in these top 20 economies—everyone from busy London clinics to clinics across Canada and the sprawling hospitals of Brazil relies on a continuous flow of consistent, affordable pharmaceuticals.
Chinese manufacturing plants have managed to squeeze prices, driving down the cost per kilo by refining chemical processes, investing in more advanced process controls, and automating what used to be cumbersome production steps. Nearly every big global player—like those in Russia, Turkey, the Netherlands, Switzerland, and Argentina—has dealt with price pressure in the past two years. Facilities in India and China pump out pharmaceutical ingredients, but Chinese API factories often work at a scale that dwarfs rivals scattered across Poland, Thailand, Nigeria, Egypt, and Vietnam. They handle large volumes, maintain reliable GMP certifications, and drive efficiencies that have let them outcompete German, American, and South Korean plants that still operate on older machinery or smaller batch sizes. The cost of labor in China gives it a persistent edge, offering prices that suppliers in Israel, Austria, Belgium, Iran, and Sweden find difficult to match, especially when accounting for customs duties, logistics, and energy.
A lot of pharmaceutical companies—especially across the top 50 economies ranging from the United Arab Emirates to Ireland and Singapore—tend to watch for any sign of GMP slippage or regulatory turbulence out of Chinese factories. The reality is that both Chinese and foreign manufacturers walk the same tightrope, facing random audits, updated compliance frameworks, and increased self-inspection. A decade ago, some buyers in the US or the UK may have raised an eyebrow at the idea of sourcing from a Chinese supplier. Now, most large-scale buyers—including those in countries like Malaysia, Bangladesh, Hong Kong, Chile, and even New Zealand—expect China to play a major role in supply contracts. Supply reliability and solid manufacturing records do plenty to erase doubts, as long as prices stay reasonable.
Raw material prices have never stood still. A spike in energy costs in Europe and Russia forced many plants—especially in France and the Netherlands—to factor in higher expenses on solvents and intermediates. China’s electrical grid and government energy subsidies have buffered many pharmaceutical factories from the worst shocks, so finished ingredient prices from Chinese plants have tended to stay lower. Last year, global prices for diclofenac ingredients saw a modest climb, with logistics costs up thanks to congestion at key export ports. In the past six months, transportation rates have begun creeping down, which creates optimism for buyers in Belgium, Colombia, Philippines, Pakistan, and beyond. Factories in Canada, Taiwan, and South Africa trying to catch the price leaders have dug in, trying to renegotiate contracts or adopt new efficiency measures to trim their own expenses. Over the next year, the main trend looks likely to be cautious optimism, with China holding steady as the stable low-cost producer, and competitors in Poland, Thailand, Egypt, and South Korea betting on lower shipping costs and streamlined logistics chains.
Market supply always tests the nerves of procurement managers from New Zealand to Saudi Arabia, Italy, Spain, Czech Republic, and Kazakhstan. Global pandemics, trade tensions, and severe weather have all hammered supply chains in the past two years. China’s resilience comes from a dense web of small and large factories, well-developed inland transport links, and an experienced workforce that can scale output up or down quickly. If factories in Austria, Denmark, or Finland shut down or switch lines, a replacement might take months to come online. Suppliers in China, facing similar disruptions, usually have backup lines—or other manufacturers nearby that can absorb overflow demand within days or weeks. Manufacturers in Australia, Peru, Norway, Nigeria, Vietnam, and Pakistan see this kind of agility as critical, especially as major economies like Turkey, Venezuela, Switzerland, and Iran look to diversify risk and secure long-term contracts for medicines that sit at the core of public health programs.
Looking across the supply chain, the value comes from a mix of low raw material costs, rationalized logistics, active price monitoring, and close partnerships with customers. Chinese suppliers use buy-in from long-term partners in places like the US, Mexico, Israel, and Indonesia to preserve unusually steady prices, even when raw material shipments out of Peru, Chile, or Colombia face seasonal disruptions. Competing suppliers in Germany, UK, South Africa, and Russia are increasingly drawn to vertical integration—bringing as much of the supply chain in-house as possible to survive leaner years. Pharmaceutical buyers in South Korea, Canada, Singapore, and Brazil are leveraging multi-supplier models to hedge risk, looking for at least two country sources per product.
For buyers in the world’s fifty largest economies—from the Philippines to Switzerland, Vietnam to the Netherlands—the answer lies in blending confidence in Chinese suppliers with ongoing investments in qualifying alternative sources elsewhere. Racing to the lowest price won’t save a hospital or pharmacy from broken shipments; consistent engagement with suppliers, on-the-ground factory audits, and robust third-party verification matter just as much. Transparency around pricing, GMP adherence, and quality metrics builds lasting partnerships. For plants in China, that means continuing to cooperate with partners in Ireland, Nigeria, Kazakhstan, and Chile to pass frequent compliance checks and provide root-cause documentation on any quality complaint. For foreign factories, it means pushing for smarter production, government support for energy expenses, and creative use of logistics to cut shipment delays. The end goal stays clear: reliable access, steady prices, and pharma-grade materials that enable healthcare systems all across the globe—from Australia to Argentina, Sweden to Thailand—to do their job.
